NCT06733987 Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
| NCT ID | NCT06733987 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Hodgkin Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2027-02-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the Departmental Diagnosis and Therapy program for chronic lymphoproliferative syndromes of the IRCCS AOU of Bologna. Peripheral blood samples will be used for the study and will be taken: * before starting treatment with pembrolizumab. * undergoing therapy with pembrolizumab (cycle 2 (C2), C3, C4, C8, C12).
Eligibility Criteria
Inclusion Criteria: * Patients of both sexes aged ≥ 18 years at enrollment * Patients affected by cHL R/R candidate to receive a treatment with Pembrolizumab * Signature of informed consent Exclusion Criteria: * none